Jerald P. Radich, MD

Jerald Radich, MD, discusses the impact of minimal residual disease on survival outcomes in patients with acute myeloid leukemia.

Jerald P. Radich, MD, discusses measuring minimal residual disease (MRD) in hematologic malignancies.

Jerald P. Radich, MD, discusses the utility of minimal residual disease in hematologic malignancies.

Jerald P. Radich, MD, discusses the impact of minimal residual disease in patients with acute versus chronic leukemias.

Jerald P. Radich, MD, discusses how the role of minimal residual disease (MRD) has evolved recently in clinical trials of hematologic malignancies.

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses compliance to the NCCN guidelines in the treatment of patients with chronic myeloid leukemia (CML).

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses treatment discontinuation off trial for patients with chronic myeloid leukemia (CML).

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses the potential of biosimilars in oncology.

​Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses which patients should receive the newly approval generic imatinib versus second-generation tyrosine-kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).

​Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses the impact of the approval of generic imatinib in chronic myelogenous leukemia (CML).